Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art.
Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art.
复制标题
DOI：
10.1016/j.smim.2010.02.001
复制
发表时间：
2010-06
影响因子：
7.8
通讯作者：
Podack ER
中科院分区：
文献类型：
--
作者：
Schreiber TH;Raez L;Rosenblatt JD;Podack ER
Despite enormous effort, promising pre-clinical data in animal studies and over 900 clinical trials in the United States, no cancer vaccine has ever been approved for clinical use. Over the past decade a great deal of progress has been in both laboratory and clinical studies defining the interactions between developing tumors and the immune system. The results of these studies provide a rationale that may help explain the failure of recent therapeutic cancer vaccines in terms of vaccine principles, in selecting which tumors are the most appropriate to target and instruct the design and implementation of state-of-the-art cancer vaccines.
登录
查看更多内容
影响因子：
6.2
作者：
Higano, Celestia S.;Schellhammer, Paul F.;Frohlich, Mark W.
通讯作者：
Frohlich, Mark W.
影响因子：
56.9
作者：
Bargou, Ralf;Leo, Eugen;Kufer, Peter
通讯作者：
Kufer, Peter
影响因子：
3.9
作者：
Hawkins, Robert E.;Macdermott, Catriona;Harrop, Richard
通讯作者：
Harrop, Richard
影响因子：
5.8
作者：
Hersey, P.;Halliday, G. M.;Menzies, S. W.
通讯作者：
Menzies, S. W.
影响因子：
3.9
作者：
Amato, Robert J.;Shingler, William;Harrop, Richard
通讯作者：
Harrop, Richard